PBM Fees Under Medicare Would Be Reported To DoJ, HHS In Senate Bill
Executive Summary
PBMs administering Medicare drug plans would be required to report all payments received from drug manufacturers to the Department of Justice and the HHS Inspector General under the Senate's Medicare legislation
You may also be interested in...
PBM Disclosure Requirements On Rx Switches Likely To Increase Costs – FTC
Pharmaceutical benefit manager disclosure requirements related to drug switches are likely to increase consumers' drug costs rather than strengthen consumer protections, the Federal Trade Commission said in its review of PBM transparency legislation under consideration in California
PBM Disclosure Requirements On Rx Switches Likely To Increase Costs – FTC
Pharmaceutical benefit manager disclosure requirements related to drug switches are likely to increase consumers' drug costs rather than strengthen consumer protections, the Federal Trade Commission said in its review of PBM transparency legislation under consideration in California
PBM/Manufacturer Therapeutic Substitution Contracts Sought In FTC Study
The Federal Trade Commission is asking pharmacy benefit management companies to submit their "therapeutic substitution" contracts with pharmaceutical manufacturers as part of a study of "conflicts of interest" in the PBM sector